Eileen M. Boyle, MD, PhD, on Predicting Treatment Response With Genomic and Immune Microenvironment Features in Multiple Myeloma

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses the key factors contributing to sustained remission when patients with newly diagnosed multiple myeloma are treated with immunotherapy and the clinical implications with regard to enhancing responses to therapy.